China’s Thalys And iCAN: Israel-Cannabis Sign MOU For Co-Investment In Cannabis & Hemp Related Startups

ISRAEL: Thalys Medical Technology, a leading Chinese healthcare conglomerate listed on the Shanghai Stock Exchange (603716.SS), signed a Memorandum of Understanding with iCAN Israel-Cannabis, Israel’s leading medical cannabis incubator. 

iCANN logoThalys and iCAN will come together to create a unique partnership to advance the development of early stage incubated companies that focus on the creation of medical technology, agricultural technology and general intellectual property focusing on the medical hemp industry.  

“Thalys and iCAN each bring unique strengths to this partnership, which is strategic in every sense.  Thalys will help iCAN’s portfolio companies enter the world’s most populous consumer market.  Thalys, which plans to co-invest in iCAN’s portfolio investments that address Chinese market needs, will have exclusive cooperation rights on iCAN’s incubated start-ups and we will have matching stakes in new investments.  I am honoured, humbled and proud to work cooperatively with one of China’s leading medical technology companies,” said Saul Kaye, CEO of iCAN.

According to the MOU, Thalys will have access to all early stage companies that iCAN is evaluating for investment, funding for co-investment, and access to the Israeli market.  Thalys will have the ability to negotiate exclusive rights with any and all of the incubated companies for the Chinese market.

Yicheng Wen, Thalys’ Board Member, stated “By pairing with a leading medical, agricultural, and technology incubator from Israel, known by many as the ‘Start-Up Nation’, Thalys advances its mission to serve the Chinese domestic healthcare market through innovation. We are excited to deepen the relationship between Chinese and Israeli entrepreneurs to accelerate the development of China’s new medical hemp industry.”

Arcview Co-Hosts Hong Kong’s First Ever Cannabis Investor Symposium

CHINA: Hong Kong’s first-ever Cannabis Investor Symposium will take place on November 1, 2018 at the W Hotel. The one-day gathering is hosted by The Arcview Group, CannaTech and URI Capital Management.

The Cannabis industry is the fastest growing market in the world and the legal cannabis business is expected to generate $57 billion globally by 2027 as countries throughout the world continue to legalize its use and demand continues to grow exponentially.

The Hong Kong Symposium will focus on the global investment opportunity but is specially curated toward the Asian market.

The most powerful cannabis business leaders and investment experts from around the world will gather to discuss the burgeoning industry.

Keynote and panel discussions will cover Cannabis and China, The Cannabis Value Chain, Market Insights: Australasia, Public and Private Investment Opportunities, Risks and Regulations, World Cannabis Policy and more.

The event is designed for those looking to gain insight into investment opportunities in the global cannabis market, family offices, money managers, venture capital firms, private equity funds, and institutional investors.

Troy Dayton, CEO of The Arcview Group adds: “The worldwide cannabis market is exploding, and Asian investors are increasingly paying attention. Up until now, pioneering Asian investors have only been able to simply read about this fascinating industry. Not anymore. We are bringing the cannabis industry to them.”

Saul Kaye, CEO of CannaTech and iCAN said of the symposium, “The time has come for serious Asian investors to enter the market. The Hong Kong event will take place days after CannaTech Sydney, Australia’s first Medical Cannabis Summit. The region’s attitude is evolving quickly, particularly with respect to Medical Cannabis and the industry needs to learn more. Currently dominated by American and Canadian investors, the time is right for the Asian investment community to join this industry. We are thrilled to partner with Arcview and URI Fund on this important event.”

Uri Capital Management added: “Cannabis usage as a medicinal plant dates back in Chinese history for thousands of years. Medicinal cannabis research is rapidly progressing, and we need to redefine our attitude towards cannabis and hemp. Asia, more specifically China, is poised to leverage its unique advantages in Hemp and agriculture to become a dominant global leader. URI is proud to become the first Chinese financial conglomerate to focus on the Asian cannabis industry and will leverage the firm’s world class research and investment resources to lead the way.”

For more information about the Hong Kong Cannabis Symposium, click here.

 

 

 

 

Vape Co. CEO: Trump’s Trade War Will Stifle The Cannabis Industry

The 25% increase in tariffs impact on vaping & cannabis

NEW YORK:  Today, The Blinc Group’s Co-CEO,  Arnaud Dumas de Rauly,  is testifying at The Office of the U.S. Trade Representative (USTR) public hearings regarding proposed tariffs on approximately $16 billion worth of Chinese products.

These proposed tariffs increases – including HTS No. 8543709930 and HTS No. 8543709940 related to vapor product devices, batteries intended for use in vaping devices, and pre filled pods and cartridges – will do great harm to American businesses, medical marijuana patients and adult use consumers while doing nothing to empower American companies to manufacture these products themselves.

The current administration’s trade war raged against China will:

  1. Reduce access to reduced risk vapor products and therapeutic cannabis products to American citizens,

  2. Not bring back jobs to America,

  3. Cut current medical marijuana and adult use States tax revenues by over 25%,

“Increasing tariffs may have worked 20 years ago, when US manufacturing was at its highest, but given the current economy, it is a major mistake to believe that this will bring jobs back to American citizens,” said Dumas de Rauly. 

With regards to taxes, “The State of Colorado has collected over $247M in Cannabis tax revenue in 2017. Considering that over the same period, cannabis vaping products comprised 25% of sales volumes, the loss of taxes due to non-availability of the products, would represent $61.75M, which represents the cost of educating 10,445 students. Yes ladies and gentlemen, this revenue is used to fund education, regulation, substance abuse prevention and treatment programs.”

For access to the full pre-hearing testimony of The Blinc Group, please click here.

China’s Marijuana Surprise

CHINA:  An economic stir is happening in China, but it’s in an industry you might not expect. With more than half of the 600 relevant patents filed with the World Intellectual Property Office now owned by Chinese companies, the country is well positioned to dominate the global cannabis market. Which is very surprising for a nation where drug trafficking is still punishable by death and mere possession of the substance can result in a lengthy spell behind bars.

Chinese investment in the cannabis market could not be more perfectly timed, as countries like the U.S. and Uruguay begin to experiment with decriminalization. Medical marijuana research has surged over the last decade as medicine and finance have coalesced to legitimize the business of cannabis. The fervor for the war on drugs that has for decades driven the policies and public opinion on marijuana decriminalization is slowly fading. In the U.S., where cannabis is nowlegal in four states, the rhetoric is moving away from issues like crime and security, to more progressive discussions on race, mass incarceration, and personal freedom.

Meanwhile, there is another emerging dimension: Western medicine is beginning to take more seriously the tradition and techniques of alternative medicine popularized by China. Part of this tradition is cannabis, which has been used to treat illnesses ranging from depression to constipation.

China is uniquely poised to take advantage of cannabis production because of its strong patent control and the fact that its production of pharmaceuticals is surpassing the West. As Dr. Luc Dechesne states: “Because cannabis in Western medicine is becoming accepted, the predominance of Chinese patents suggests that pharmaceutical sciences are evolving quickly in China, outpacing Western capabilities.” China is already one of the leading exporters of hemp and is well positioned to benefit from any future boom in cannabis.

 

Legalizing Marijuana Does Not Mean the U.S. Would Lose Ground to China

NEW YORK: The legalization of marijuana, effective New Year’s Day in Colorado and Washington, has divided American journalists, who seemed to spend much of the last three days re-litigating the subject.

On Thursday, The New York Times‘ David Brooks wrote a column disclosing his youthful use of the drug and why, as a result, he opposes legalizing marijuana, while the very same day Ruth Marcus wrote practically the same piece in The Washington Post. [Read more…]

Legalizing Marijuana Does Not Mean the U.S. Would Lose Ground to China

NEW YORK: The legalization of marijuana, effective New Year’s Day in Colorado and Washington, has divided American journalists, who seemed to spend much of the last three days re-litigating the subject.

On Thursday, The New York Times‘ David Brooks wrote a column disclosing his youthful use of the drug and why, as a result, he opposes legalizing marijuana, while the very same day Ruth Marcus wrote practically the same piece in The Washington Post. [Read more…]

As Cannabis Is Widely Legalized, China Cashes In On An Unprecedented Boom

CHINA: Almost 5,000 years ago, Chinese physicians recommended a tea made from cannabis leaves to treat a wide variety of conditions including gout and malaria. Today, as the global market for marijuana experiences an unprecedented boom after being widely legalized, it is China that again appears to have set its eyes on dominating trade in the drug.

The communist country is well placed to exploit the burgeoning cannabis trade with more than half of the patents relating to or involving cannabis originating in China. According to the World Intellectual Property Organization (Wipo), Chinese firms have filed 309 of the 606 patents relating to the drug. [Read more…]